frontiers in Pharmacology

ERRATUM
published: 05 April 2019
doi: 10.3389/fphar.2019.00418

Erratum: Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines

*Frontiers Production Office**

Frontiers Media SA, Lausanne, Switzerland

OPEN ACCESS

Approved by:
Frontiers Editorial Office, Frontiers Media SA, Switzerland

***Correspondence:**
Frontiers Production Office
production.office@frontiersin.org

Specialty section:
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology

Received: *28 March 2019*
Accepted: *03 April 2019*
Published: *05 April 2019*

Citation:
Frontiers Production Office (2019) Erratum: Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines. Front. Pharmacol. 10:418. doi: 10.3389/fphar.2019.00418

Keywords: cannabinoid receptor 2 (CB_2), G protein-coupled receptor, signalling bias, signalling, synthetic cannabinoid, drug design, medicinal chemistry, immune therapeutics

An Erratum on

Cannabinoid Receptor 2 Signalling Bias Elicited by 2,4,6-Trisubstituted 1,3,5-Triazines
by Oyagawa, C. R. M., de la Harpe, S. M., Saroz, Y., Glass, M., Vernall, A. J., and Grimsey, N. L. (2018). Front. Pharmacol. 9:1202. doi: 10.3389/fphar.2018.01202

Due to a production error, 24 references with more than six authors were listed in the Reference list without "et al." The references affected are Bouaboula et al. (1993, 1996); Felder et al. (1995); Galiegue et al. (1995); Favata et al. (1998); Portier et al. (1999); Kilts et al. (2002); Karsak et al. (2005); Wright et al. (2005); Ofek et al. (2006); Jiang et al. (2007); Valant et al. (2008); Cencioni et al. (2010); Hurst et al. (2010); Schuehly et al. (2011); van der Stelt et al. (2011); Kleyer et al. (2012); Odan et al. (2012); Shonberg et al. (2013); Brailoiu et al. (2014); Herenbrink et al. (2016); Finlay et al. (2017); Soethoudt et al. (2017) and Yrjölä et al. (2015).

The publisher apologizes for this mistake. The original version of this article has been updated.

REFERENCES

Bouaboula, M., Poinot-Chazel, C., Marchand, J., Canat, X., Bourrie, B., Rinaldi-Carmona, M., et al. (1996). Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. *Eur. J. Biochem.* 237, 704–711. doi: 10.1111/j.1432-1033.1996.0704p.x

Bouaboula, M., Rinaldi, M., Carayon, P., Carillon, C., Delpech, B., Shire, D., et al. (1993). Cannabinoid-receptor expression in human leukocytes. *Eur. J. Biochem.* 214, 173–180. doi: 10.1111/j.1432-1033.1993.tb17910.x

Brailoiu, G. C., Deliu, E., Marcu, J., Hoffman, N. E., Console-Bram, L., Zhao, P., et al. (2014). Differential activation of intracellular versus plasmalemmal CB2 cannabinoid receptors. *Biochemistry* 53, 4990–4999. doi: 10.1021/bi500632a

Cencioni, M. T., Chiurchiu, V., Catanzaro, G., Borsellino, G., Bernardi, G., Battistini, L., et al. (2010). Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors. *PLoS ONE* 5:e8688. doi: 10.1371/journal.pone.0008688

Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, W. S., et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. *J. Biol. Chem.* 273, 18623–18632. doi: 10.1074/jbc.273.29.18623

Felder, C. C., Joyce, K. E., Briley, E. M., Mansouri, J., Mackie, K., Blond, O., et al. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. *Mol. Pharmacol.* 48, 443–450.

Finlay, D. B., Cawston, E. E., Grimsey, N. L., Hunter, M. R., Korde, A., Vemuri, V. K., et al. (2017). Gas signalling of the CB1 receptor and the influence of receptor number. *Br. J. Pharmacol.* 174, 2545–2562. doi: 10.1111/bph.13866

Galiegue, S., Mary, S., Marchand, J., Dussossoy, D., Carriere, D., Carayon, P., et al. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. *Eur. J. Biochem.* 232, 54–61.

Herenbrink, C. K., Sykes, D. A., Donthamsetti, P., Canals, M., Coudrat, T., Shonberg, J., et al. (2016). The role of kinetic context in apparent biased agonism at GPCRs. *Nat. Commun.* 7:10842. doi: 10.1038/ncomms10842

Hurst, D. P., Grossfield, A., Lynch, D. L., Feller, S., Romo, T. D., Gawrisch, K., et al. (2010). A lipid pathway for ligand binding is necessary for a cannabinoid G protein-coupled receptor. *J. Biol. Chem.* 285, 17954–17964. doi: 10.1074/jbc.M109.041590

Jiang, L. I., Collins, J., Davis, R., Lin, K.-M., DeCamp, D., Roach, T., et al. (2007). Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-Phosphate/G(13) pathway. *J. Biol. Chem.* 282, 10576–10584. doi: 10.1074/jbc.M609695200

Karsak, M., Cohen-Solal, M., Freudenberg, J., Ostertag, A., Morieux, C., Kornak, U., et al. (2005). Cannabinoid receptor type 2 gene is associated with human osteoporosis. *Hum. Mol. Genet.* 14, 3389–3396. doi: 10.1093/hmg/ddi370

Kilts, J. D., Connery, H. S., Arrington, E. G., Lewis, M. M., Lawler, C. P., Oxford, G. S., et al. (2002). Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. *J. Pharmacol. Exp. Ther.* 301, 1179–1189. doi: 10.1124/jpet.301.3.1179

Kleyer, J., Nicolussi, S., Taylor, P., Simonelli, D., Furger, E., Anderle, P., et al. (2012). Cannabinoid receptor trafficking in peripheral cells is dynamically regulated by a binary biochemical switch. *Biochem. Pharmacol.* 83, 1393–1412. doi: 10.1016/j.bcp.2012.02.014

Odan, M., Ishizuka, N., Hiramatsu, Y., Inagaki, M., Hashizume, H., Fujii, Y., et al. (2012). Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent. *Bioorg. Med. Chem. Lett.* 22, 2803–2806. doi: 10.1016/j.bmcl.2012.02.072

Ofek, O., Karsak, M., Leclerc, N., Fogel, M., Frenkel, B., Wright, K., et al. (2006). Peripheral cannabinoid receptor, CB2, regulates bone mass. *Proc. Natl. Acad. Sci. U.S.A.* 103, 696–701. doi: 10.1073/pnas.0504187103

Portier, M., Rinaldi-Carmona, M., Pecceu, F., Combes, T., Poinot-Chazel, C., Calandra, B., et al. (1999). SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. *J. Pharmacol. Exp. Ther.* 288, 582–589.

Schuehly, W., Paredes, J. M., Kleyer, J., Huefner, A., Anavi-Goffer, S., Raduner, S., et al. (2011). Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. *Chem. Biol.* 18, 1053–1064. doi: 10.1016/j.chembiol.2011.05.012

Shonberg, J., Herenbrink, C. K., López, L., Christopoulos, A., Scammells, P. J., Capuano, B., et al. (2013). A structure–activity analysis of biased agonism at the dopamine D2 receptor. *J. Med. Chem.* 56, 9199–9221. doi: 10.1021/jm401318w

Soethoudt, M., Grether, U., Fingerle, J., Grim, T. W., Fezza, F., de Petrocellis, L., et al. (2017). Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity. *Nat. Commun.* 8:13958. doi: 10.1038/ncomms13958

Valant, C., Gregory, K. J., Hall, N. E., Scammells, P. J., Lew, M. J., Sexton, P. M., et al. (2008). A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. *J. Biol. Chem.* 283, 29312–29321. doi: 10.1074/jbc.M803801200

van der Stelt, M., Cals, J., Broeders-Josten, S., Cottney, J., van der Doelen, A. A., Hermkens, M., et al. (2011). Discovery and optimization of 1-(4-(Pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives as a novel class of selective cannabinoid CB2 receptor agonists. *J. Med. Chem.* 54, 7350–7362. doi: 10.1021/jm200916p

Wright, K., Rooney, N., Feeney, M., Tate, J., Robertson, D., Welham, M., et al. (2005). Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. *Gastroenterology* 129, 437–453. doi: 10.1016/j.gastro.2005.05.026

Yrjölä, S., Sarparanta, M., Airaksinen, A. J., Hytti, M., Kauppinen, A., Pasonen-Seppänen, S., et al. (2015). Synthesis, *in vitro* and *in vivo* evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists. *Eur. J. Pharm. Sci.* 67, 85–96. doi: 10.1016/j.ejps.2014.11.003